Literature DB >> 11745849

Color Doppler sonography for ventral hernias in patients with acute abdomen: preliminary findings.

R J Liang1, H P Wang, S P Huang, M S Wu, J T Lin.   

Abstract

PURPOSE: We assessed the usefulness of color Doppler sonography (CDUS) in evaluating the vascular status of ventral hernias and distinguishing incarcerated from nonincarcerated ventral hernias.
METHODS: In this prospective study, 10 patients who presented with acute abdomen and had ventral hernias underwent CDUS from August 1999 to May 2000. Patient age and sex and the clinical severity, mode of therapy, and outcome in these 10 patients were evaluated in relationship to the CDUS findings.
RESULTS: Five patients had readily visible flow in the bowel within the hernial sac on CDUS. Two of these 5 had spontaneous reduction under conservative treatment, and 3 had asymptomatic ventral hernias with acute abdomen caused by spontaneous bacterial peritonitis. Barely visible flow was visualized in the bowel by CDUS in 4 other patients. Three of these underwent emergency surgery because of peritoneal signs; 2 of them were found to have ischemic changes in the bowel. The fourth patient underwent a successful manual reduction. The remaining patient had absent flow in the bowel on CDUS and underwent emergency surgery, which revealed gangrenous changes in the bowel.
CONCLUSIONS: The intensity of the Doppler signals on CDUS appears to be a promising predictor of bowel viability in cases of ventral hernia. Thus, CDUS should impact the determination of the treatment plan, including whether to provide conservative treatment or surgery. Copyright 2001 John Wiley & Sons, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11745849     DOI: 10.1002/jcu.10003

Source DB:  PubMed          Journal:  J Clin Ultrasound        ISSN: 0091-2751            Impact factor:   0.910


  1 in total

Review 1.  [Diagnostic laparoscopy in acute abdomen].

Authors:  R Keller; M Kleemann; P Hildebrand; U J Roblick; H-P Bruch
Journal:  Chirurg       Date:  2006-11       Impact factor: 0.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.